The Identification of Novel Prognostic Markers in Melanoma
Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples
1 other identifier
observational
500
1 country
1
Brief Summary
The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2008
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2008
CompletedFirst Submitted
Initial submission to the registry
October 26, 2009
CompletedFirst Posted
Study publicly available on registry
October 27, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedOctober 27, 2009
October 1, 2009
1 year
October 26, 2009
October 26, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Given that the nature of the research is qualitative, there is no primary outcome measure.
Study Arms (2)
Malignant melanoma tumour tissue
Benign pigmented lesions & other skin cancers
Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
Eligibility Criteria
Group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital
You may qualify if:
- Diagnosis of melanoma
- Adequate paraffin-embedded material available for analysis.
- Adequate clinical follow-up information
- Written informed consent where applicable
You may not qualify if:
- Inadequate paraffin-embedded material available
- Inadequate clinical follow-up information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Professor Martin Gore
Royal Marsden NHS Foundation Trust
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 26, 2009
First Posted
October 27, 2009
Study Start
December 1, 2008
Primary Completion
December 1, 2009
Study Completion
December 1, 2009
Last Updated
October 27, 2009
Record last verified: 2009-10